Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2024 Dec 31

PMID 39739243

Authors

Daniel Tobias Michaeli

Thomas Michaeli

Affiliations

Soon will be listed here.

Abstract

Objectives: For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication. Under weighted-average pricing, a single drug price is calculated that reflects the value and/or volume of each indication. This study estimates price reductions and cost savings for cancer drugs under value-based indication-specific pricing and weighted-average pricing.

Methods: We collected data on US Food and Drug Administration (FDA)-approved cancer drugs and indications (2003-2020) from FDA labels, the Global Burden of Disease study, clinicaltrials.gov, and Medicare and Medicaid. A multivariable regression analysis, informed by characteristics of original indications, was used to predict value-based indication-specific prices for supplemental indications. These indication-specific prices were combined with each indication's prevalence data to estimate value-based weighted-average prices and potential cost savings under each policy.

Results: We identified 123 cancer drugs with 308 indications. Medicare and Medicaid spent a total of $28.2 billion on these drugs in 2020. Adopting value-based indication-specific pricing would increase drug prices by an average of 3.9%, with cost savings of $3.0 billion (10.6%). However, 43.7% higher prices for ultra-rare diseases would increase spending by 16.8% ($44 million). Adopting value-based weighted-average pricing would reduce prices by an average of 4.6% and spending by $3.0 billion (10.6%). Under weighted-average pricing, prices for and spending on ultra-rare diseases would be reduced by 22.6% and $55 million, respectively.

Conclusions: Value-based indication-specific and weighted-average pricing could help to align the value and price of new indications, thereby reducing expenditure on drugs with multiple indications.

References

Michaeli D, Michaeli T . Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. J Clin Oncol. 2022; 40(35):4095-4106. DOI: 10.1200/JCO.22.00535. View

Michaeli D, Michaeli T . Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology. Value Health. 2023; 26(11):1590-1600. DOI: 10.1016/j.jval.2023.06.020. View

Chua K, Kimmel L, Conti R . Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases. Health Aff (Millwood). 2021; 40(3):453-460. PMC: 8011952. DOI: 10.1377/hlthaff.2020.01442. View

Michaeli T, Michaeli D . Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending. Value Health. 2024; 27(4):449-457. DOI: 10.1016/j.jval.2024.01.002. View

Tu S, Nagar S, Kesselheim A, Lu Z, Rome B . Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation. JAMA. 2023; 329(18):1607-1608. PMC: 10170330. DOI: 10.1001/jama.2023.3079. View

Michaeli D, Michaeli T, Albers S, Boch T, Michaeli J . Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2023; 25(6):979-997. PMC: 11283430. DOI: 10.1007/s10198-023-01639-x. View

Campillo-Artero C, Puig-Junoy J, Segu-Tolsa J, Trapero-Bertran M . Price Models for Multi-indication Drugs: A Systematic Review. Appl Health Econ Health Policy. 2019; 18(1):47-56. DOI: 10.1007/s40258-019-00517-z. View

Chandra A, Garthwaite C . The Economics of Indication-Based Drug Pricing. N Engl J Med. 2017; 377(2):103-106. DOI: 10.1056/NEJMp1705035. View

Pearson S, Dreitlein W, Henshall C, Towse A . Indication-specific pricing of pharmaceuticals in the US healthcare system. J Comp Eff Res. 2017; 6(5):397-404. DOI: 10.2217/cer-2017-0018. View

10.

Persson U, Norlin J . Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations. Appl Health Econ Health Policy. 2018; 16(2):157-165. DOI: 10.1007/s40258-018-0377-7. View

11.

Yeung K, Li M, Carlson J . Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. J Manag Care Spec Pharm. 2017; 23(10):1010-1015. PMC: 10398211. DOI: 10.18553/jmcp.2017.23.10.1010. View

12.

Meher B, Padhy B . Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Trop Doct. 2020; 50(2):157-159. DOI: 10.1177/0049475520903644. View

13.

Mestre-Ferrandiz J, Zozaya N, Alcala B, Hidalgo-Vega A . Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. Pharmacoeconomics. 2018; 36(12):1407-1420. DOI: 10.1007/s40273-018-0716-4. View

14.

Bach P . Indication-specific pricing for cancer drugs. JAMA. 2014; 312(16):1629-30. DOI: 10.1001/jama.2014.13235. View

15.

Garrison Jr L, Veenstra D . The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. 2009; 12(8):1118-23. DOI: 10.1111/j.1524-4733.2009.00572.x. View

16.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

17.

Vokinger K, Kesselheim A . Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe. Nat Rev Clin Oncol. 2021; 19(1):1-2. DOI: 10.1038/s41571-021-00561-6. View

18.

Sarpatwari A, DiBello J, Zakarian M, NajafZadeh M, Kesselheim A . Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Med. 2019; 16(7):e1002872. PMC: 6667132. DOI: 10.1371/journal.pmed.1002872. View

19.

Michaeli D, Mills M, Kanavos P . Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022; 20(5):757-768. PMC: 9385843. DOI: 10.1007/s40258-022-00737-w. View

20.

Bach P . Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009; 360(6):626-33. DOI: 10.1056/NEJMhpr0807774. View